Drugs

This Is Not Your Grandfather’s Weed

/ SupremeCmdr / 1 Comment

So let me be the doctor who says it plainly. This is not the mild plant of the 1970s. Then, cannabis was 1-3% THC. Today’s products run 15-25%, and concentrates — dabs, vapes, wax — hit 70-90%+. When people say “it’s natural, it’s harmless,” they’re defending a product that no longer exists. We didn’t legalize the old plant. We industrialized a far more potent one.

A Danish registry study followed 6,788 people diagnosed with substance-induced psychosis. Overall, 32.2 percent later developed schizophrenia-spectrum or bipolar disorder. Among those with cannabis-induced psychosis, 47.4 percent later received one of those diagnoses.

A large Ontario cohort found that approximately 26 percent of people who presented to an emergency department with cannabis-induced psychosis were diagnosed with a schizophrenia-spectrum disorder within three years. The corresponding rate after alcohol-induced psychosis was approximately 8.9 percent. Among the substances studied, cannabis-induced psychosis carried the highest risk of later transition to schizophrenia-spectrum illness. Is it cannabis-induced psychosis or bipolar disorder? https://kevinmd.com/2026/07/is-it-cannabis-induced-psychosis-or-bipolar-disorder.html

YIKES.

GLP-1’s – Anti-Aging Drug?

/ SupremeCmdr / 1 Comment

Enjoy. But please read the entire article before you go online, buy a GLP-1 and start injecting yourself.

The Anti-Aging Drug We Keep Calling a Weight-Loss Shot

https://afshine.substack.com/p/the-anti-aging-drug-we-keep-calling?r=22fro&utm_campaign=post&utm_medium=web&triedRedirect=true

GLP-1 Just $50 a Month!!!

/ SupremeCmdr / Leave a comment

Starting July 1, 2026 Medicare covers certain GLP-1 drugs under the Medicare GLP-1 Bridge program. This temporary program is available nationwide (including all states and U.S. territories) to certain people with Medicare drug coverage (Part D). https://www.medicare.gov/coverage/weight-loss-drugs

You must be 18 or older and meet one of these requirements when you start GLP-1 therapy:


You have a body mass index (BMI) of 35 or more.


You have a BMI between 30-34.99 and have at least one of these conditions:
Diastolic heart failure (also called heart failure with preserved ejection fraction)
Uncontrolled high blood pressure (also called hypertension)
Chronic kidney disease at stage 3a or higher
Prediabetes
A previous heart attack (also called myocardial infarction) or stroke
Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms


You have a BMI between 27-29.99 and have at least one of these conditions:
Prediabetes
A previous heart attack (also called myocardial infarction) or stroke
Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms

Yes, I loved writing the click bait title to this post.

GLP-1s (it’s kind of a mess)

/ SupremeCmdr / Leave a comment

“But the real question is what is the quality of the weight regain and what is the shift in people’s metabolism, and it seems to be very bad,” she said. “Ongoing studies that haven’t been published yet suggest that hypertension comes back. All the inflammatory markers come back, and lipids go up. And if you have diabetes, it gets worse. Overall, it’s kind of a mess…As these studies and others showed, most people regain the weight. Whether or not they regain all the weight depends in part on diabetes and insulin and many other factors, but people will likely regain most of their weight.”

“But the message isn’t that you regain the weight. The message is that you may be less healthy when you regain the weight. That’s why we need to couple the drugs with lifestyle interventions. And it’s why people who just want to lose 5 or 10 pounds really need to consider that lifestyle change, hard as it is, is the better way to do it.”

Anne Peters, MD, professor Keck School of Medicine of the University of Southern California

Less Weight Regain, More Health Loss after Stopping GLP-1s? – Medscape – March 05, 2026 – https://www.medscape.com/viewarticle/less-weight-regain-more-health-loss-after-stopping-glp-1s-2026a10006rv?

I never envisioned developing an obsession with pharmaceuticals. And after many years of endless blogging into the void I learned I could link to previous posts like this: https://lifeunderwriter.net/tag/glp-1-receptor-agonist/

The learning never stops.

GLP-1s and the Risk for Malnutrition

/ SupremeCmdr / 1 Comment

“We see cases where people take a GLP-1 medication and become so severely malnourished that they need to be hospitalized,” said Rebecca Boswell, PhD, director of Penn Medicine Princeton Center for Eating Disorders, in Philadelphia. “It’s not uncommon.” The Scary Health Risk That Can Sneak Up on GLP-1 Users – Medscape – January 19, 2026. https://www.medscape.com/viewarticle/scary-health-risk-can-sneak-glp-1-users-2026a10001pi

Yikes.

People return to their baseline weight and lose all cardiometabolic benefits in less than 2 years after stopping semaglutide or tirzepatide, a new meta-analysis found. Weight Regain, Health Benefit Loss Rapid When GLP-1s Stopped – Medscape – January 08, 2026. https://www.medscape.com/viewarticle/weight-regain-health-benefit-loss-rapid-when-glp-1s-stopped-2026a10000kr?

YIKES.

You see, cures are passée. Cures kill markets. Getting the population properly hooked on a pharmaceutical treatment for a ‘chronic’ condition is where the serious money is. “Our core insight was simple and grim: it’s far easier—and infinitely more profitable—to convince healthy people that they’re sick than to develop genuine cures for the truly ill.“

Twenty years later, the hustle is bigger, slicker, and more dangerous than ever. Watching that hustle unfold with weight loss drugs feels weirdly ominous, like watching a slow-moving train wreck you can’t peel your eyes off of. You know there’ll be carnage and bodies, vast fortunes won and lost, and humanity left just a little bit poorer. We have often documented the pharmaceutical industry’s proven ability to create enormously lucrative markets overnight, by inventing and selling diseases. Now watch as all that ingenuity and energy gets pointed at one of the biggest problems bewitching humanity: human fatness. The Seven Deadly Sins of Weight Loss Drugs – https://brownstone.org/articles/the-seven-deadly-sins-of-weight-loss-drugs/

YIKES!

This will not end well.

Complications? What Complications? (just another GLP-1 receptor agonist post)

My Statin Comes From India

/ SupremeCmdr / 3 Comments

According to the USP, the bulk of the APIs come from India. That country is responsible for 50% of the active pharmaceutic ingredients. China is not far behind at 32%. The European Union supplies 10%. That’s a big change since 2000. Back then, European countries like France, Germany, Switzerland and Denmark supplied 42% of the APIs. Drug Recalls From India – Can You Trust Foreign-Made Generics? – https://www.peoplespharmacy.com/articles/more-drug-recalls-from-india-do-you-trust-foreign-made-generics

Dozens of companies received approval from the FDA over the years to sell metoprolol and bupropion in the U.S. Yet from 2018 to 2024, the agency reported running only 2 tests on metoprolol and 7 on bupropion through its quality surveillance program — in each case, by pulling a sample from a single drug maker. In many of those years, the drugs weren’t tested at all, FDA records show. Those that were assessed received passing results. The FDA Often Doesn’t Test Generic Drugs for Quality Concerns, So ProPublica Did – https://www.propublica.org/article/fda-generic-drug-testing

ClinCalc DrugStats Database – https://clincalc.com/DrugStats/

Both articles are long reads but worth your time.

Yikes.

Antidepressant Prescriptions Increase 130% for Teenage Girls

/ SupremeCmdr / Leave a comment

The increasing rate of mental health disorders among children and adolescents is a concerning trend that has been observed for several decades, with survey studies revealing dramatic increases in anxiety, depression, and suicidal ideation.1 In the United States, suicide ranks as the second leading cause of death for those aged 10 to 19 years and the third leading cause of death for those aged 15 to 24 years.2 Antidepressant Prescriptions and Mental Health – https://publications.aap.org/pediatrics/article/153/3/e2023064677/196661/Antidepressant-Prescriptions-and-Mental-Health

Between January 2016 and December 2022, the monthly antidepressant dispensing rate increased 66.3%, from 2575.9 to 4284.8. Before March 2020, this rate increased by 17.0 per month (95% confidence interval: 15.2 to 18.8). The COVID-19 outbreak was not associated with a level change but was associated with a slope increase of 10.8 per month (95% confidence interval: 4.9 to 16.7). The monthly antidepressant dispensing rate increased 63.5% faster from March 2020 onwards compared with beforehand. In subgroup analyses, this rate increased 129.6% and 56.5% faster from March 2020 onwards compared with beforehand among females aged 12 to 17 years and 18 to 25 years, respectively. In contrast, the outbreak was associated with a level decrease among males aged 12 to 17 years and was not associated with a level or slope change among males aged 18 to 25 years. Antidepressant Dispensing to US Adolescents and Young Adults: 2016–2022 – https://publications.aap.org/pediatrics/article/153/3/e2023064245/196655/Antidepressant-Dispensing-to-US-Adolescents-and?autologincheck=redirected

Between 2020 and 2022, antidepressant prescriptions for girls aged 12-17 skyrocketed by 130%. Antidepressants Increase 130% for Teen Girls, Drop 7% For Boys – https://brownstone.org/articles/antidepressants-increase-130-for-teen-girls-drop-7-for-boys/

Yikes.

Ketamine in the UK

/ SupremeCmdr / 3 Comments

Acute harms of ketamine use relate to vulnerability and injuries. Long term use can seriously harm both physical and mental health, diminishing quality of life, affecting personal relationships, and impairing academic or professional performance.9 Ketamine induced uropathy from ulceration and thickening of the bladder is a common and serious complication. In the UK, 27% of regular ketamine users report at least one urological symptom—dysuria, frequency, incontinence, haematuria, or retention—with severity correlated with dose and frequency of use.10 Treatment requires abstinence.11 If abstinence is not achieved, irreversible bladder and kidney damage can occur, requiring urinary tract reconstruction. Long term ketamine use is also associated with “K cramps”—severe abdominal pain. This may be related to liver disease that is similar to primary sclerosing cholangitis but less inflammatory and progressive.12 Acute harms of ketamine use relate to vulnerability and injuries. Long term use can seriously harm both physical and mental health, diminishing quality of life, affecting personal relationships, and impairing academic or professional performance.9 Ketamine induced uropathy from ulceration and thickening of the bladder is a common and serious complication. In the UK, 27% of regular ketamine users report at least one urological symptom—dysuria, frequency, incontinence, haematuria, or retention—with severity correlated with dose and frequency of use.10 Treatment requires abstinence.11 If abstinence is not achieved, irreversible bladder and kidney damage can occur, requiring urinary tract reconstruction. Long term ketamine use is also associated with “K cramps”—severe abdominal pain. This may be related to liver disease that is similar to primary sclerosing cholangitis but less inflammatory and progressive.12 — Non-prescribed ketamine use is rising in the UK – https://doi.org/10.1136/bmj.r1167

Yikes.

Update 07.05.25 – https://www.bbc.com/news/articles/c70r1xdyy59o

One Toke Over the Line

/ SupremeCmdr / Leave a comment

A wave of recent research points to reasons for concern for older users, with cannabis-related emergency room visits and hospitalizations rising, and a Canadian study finding an association between such acute care and subsequent dementia. Older people are more apt than younger ones to try cannabis for therapeutic reasons: to relieve chronic pain, insomnia, or mental health issues, though evidence of its effectiveness in addressing those conditions remains thin, experts said. As Cannabis Users Age, Health Risks Appear To Grow – https://kffhealthnews.org/news/article/cannabis-medical-use-older-adults-health-risks/

Then…

And now…

“Our brains are more sensitive to psychoactive substances as we age.” Dr. Benjamin Han

Don’t you know I’m just waiting for the train that goes home, sweet Mary.